WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentCHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias
View the documentCYCLOOXYGENASE-2 INHIBITORS - Plans to review all medicines in this class
View the documentETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis
View the documentHERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada
View the documentINFLUENZA VIRUS VACCINE - Interactions with drugs
View the documentMEDROXY PROGESTERONE - Effect on bone mineral density
View the documentPAMIDRONATE DISODIUM, ZOLEDRONIC ACID - Spontaneous reports of osteonecrosis of the jaw
View the documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - ADRAC reviews use in children and adolescents
View the documentTERBINAFINE - Reports of blood dyscrasias
View the documentTRICYCLIC ANTIDEPRESSANTS - Overdose risk
View the documentFEATURE
 

ETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis

Norway. The Norwegian Medicines Control Agency (NMCA) has issued a reminder that ethinylestradiol/ cyproterone (Diane) is associated with an increased risk of thrombosis. The NMCA has received 26 reports of adverse reactions associated with Diane, including 15 of venous thrombosis, two of which were fatal. They note that ethinylestradiol/ cyproterone (Diane) should be used with the same caution as oral contraceptives, and should not be used in women with known risk factors for thrombosis, such as smoking, obesity and a personal or family history of thrombosis.

Reference:

Nytt om Legemidler, 11 August 2004. Available on the Internet at www.legemiddelverket.no

to previous section to next section
 

Last updated: May 3, 2013